CRO Tigermed Consulting Revs Up Expansion With Fund Injection
This article was originally published in PharmAsia News
Tigermed Consulting, one of China's largest CROs, has accepted the first round of capital injection from Qiming Venture Partners and will move into a rapid expansion stage. The funds will be used to improve the firm's high-quality service delivery system as well as recruit top talent worldwide to gear up for more international CRO projects. As one of the few CROs in China that can conduct global multicenter trials, Tigermed positions itself as a rival of multinational CRO Quintiles, with focus on talents rather than clients. The company boasts more than 50 percent of its employees are armed with a Master's or higher degree, and a staff turnover rate lower than 10 percent. Tigermed's business in 2007 outperformed its 100 percent growth the previous year. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.